Smokers were younger (45 versus 53 years; P = 0.003), with no differences in sex, race, or body mass index. Nonsmokers had a higher prevalence of diabetes mellitus (27.4% versus 16.9%; P = 0.048) and were more often on dialysis (32.1% versus 19.1%; P = 0.020). Preoperative laboratory values were comparable, as were wound class, American Society of Anesthesiologists score, operative time, and length of stay. Major (2.2% versus 7.2%) and total complications (16.9% versus 14.3%) were also comparable between smokers and nonsmokers; however, smokers required intraoperative transfusions more frequently (14.6% versus 5.5%; P = 0.006). Smokers and nonsmokers also experienced similar reoperation (2.1% versus 6.7%) and readmission rates (3.4% versus 3.8%). Regression analysis revealed that among replantation/revascularization patients, preoperative diabetes mellitus was a strong predictor for 30-day reoperations (OR, 5.8; 95% CI, 1.1-30.4) and white race was a significant predictor of 30-day major complications (OR, 3.3; 95% CI, 1.1-10.2), all P ≤ 0.038. Preoperative smoking history of ≤1 year was not found to be a predictor of any adverse 30-day outcomes.
RESULTS:
Smokers were younger (45 versus 53 years; P = 0.003), with no differences in sex, race, or body mass index. Nonsmokers had a higher prevalence of diabetes mellitus (27.4% versus 16.9%; P = 0.048) and were more often on dialysis (32.1% versus 19.1%; P = 0.020). Preoperative laboratory values were comparable, as were wound class, American Society of Anesthesiologists score, operative time, and length of stay. Major (2.2% versus 7.2%) and total complications (16.9% versus 14.3%) were also comparable between smokers and nonsmokers; however, smokers required intraoperative transfusions more frequently (14.6% versus 5.5%; P = 0.006). Smokers and nonsmokers also experienced similar reoperation (2.1% versus 6.7%) and readmission rates (3.4% versus 3.8%). Regression analysis revealed that among replantation/revascularization patients, preoperative diabetes mellitus was a strong predictor for 30-day reoperations (OR, 5.8; 95% CI, 1.1-30.4) and white race was a significant predictor of 30-day major complications (OR, 3.3; 95% CI, 1.1-10.2), all P ≤ 0.038. Preoperative smoking history of ≤1 year was not found to be a predictor of any adverse 30-day outcomes.
CONCLUSIONS:
Smoking as a comorbidity is frequently seen in upper extremity replantation/revascularization patients. Nonsmokers more frequently had comorbid diabetes mellitus and were on dialysis. Smoking history was not associated with increased major or minor complication, readmission, or reoperation rates in the 30-day postoperative period following upper extremity replantation/revascularization. Among replantation/ revascularization patients, diabetes mellitus was a strong predictor for 30-day reoperations. The impact of diabetic control on outcomes in this population is worth further investigation. 
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Separating Fact From Fiction: A Longitudinal Examination of Chronic Regional Pain Syndrome Following Treatment for Dupuytren's Contracture
Presenter: Danielle H. Rochlin, MD
Co-Authors: Clifford Sheckter, MD; Ellen Satteson, MD; Paige Fox, MD, PhD; Catherine Curtin, MD
Affiliation: Stanford University, Palo Alto, CA BACKGROUND: Rates of chronic regional pain syndrome (CRPS) following Dupuytren's contracture release remain unclear. Rates have been reported to range from 2.4% to 18.5% based on single institution case series. 1, 2 This study sought to provide a national perspective on the incidence of CRPS following treatment of Dupuytren's contracture and to identify patient factors to target for risk reduction. 
METHODS:
Hand Abstracts
CONCLUSIONS: Based on this study, the incidence of CRPS type 1 following treatment for Dupuytren's contracture is likely lower than previously reported. Risk factors include younger age, female gender, and more extensive operative procedures, particularly those involving fasciectomy with release of ≥1 digits. Patients with these characteristics should be targeted for pre-and postoperative risk reduction measures to limit the development of CRPS. 
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Dexamethasone for the Reduction of Postoperative Pain Following Open Carpal Tunnel Release: A Randomized Controlled Trial
Presenter: Andrew Penn Worden, MD
Co-Authors: Aamir Siddiqui, MD; Peter Janevski, MD; Jain Joseph, MD Affiliation: Henry Ford Hospital, Detroit, MI
INTRODUCTION:
Carpal tunnel syndrome is one of the most common neuropathies seen in the upper limb. Once the diagnosis is made, multiple treatment modalities are available for management of this condition. Conservative treatments include wrist splinting and corticosteroid injection. Injections often provide symptomatic relief for patients with mild to moderate disease, especially for pain. 1 These injections are usually given either as sole treatment, or as a bridge before surgery can be performed. Definitive carpal tunnel release (CTR) surgery is performed either awake with local anesthesia or under procedural anesthesia. Postoperative pain is typically treated with a combination of NSAIDs and narcotics. Nationally, overconsumption of narcotics is a critical issue. The use of steroids in conjunction with local anesthesia has not been studied in the literature. Our objective was to determine whether the addition of dexamethasone to the local anesthesia given during CTR will reduce postoperative pain and the consumption of narcotics postoperatively.
METHODS:
We conducted a randomized, double-blinded study at a single academic institute. Patients undergoing an elective CTR surgery were included. Exclusion criteria included uncontrolled diabetics, minors, traumatic or emergent case, and patients undergoing a concomitant surgery. Included patients were randomized to either the control or treatment arms. Patients in the treatment arm were given an injection of 10 mg dexamethasone with their local anesthesia at surgery versus local anesthesia alone for the control group. Postoperatively, patients logged their pain scores on a 0-10 scale at set time intervals of 8 hours, 24 hours, 48 hours, 72 hours, and 1 week postoperatively. Patients were also asked to record how many narcotic, acetaminophen, or NSAID pain pills they used. Two-sample Wilcoxon and Matlab-pairs signed-rank tests were then performed to analyze the data. P values were adjusted with Hochberg's method.
RESULTS:
Eighty-one patients were enrolled: 40 in the treatment arm and 41 in the control arm. Average pain scores were lower in the steroid group at 8 hours (2.23 SD 3.04 versus 3.45 SD 2.94; P = 0.017), 24 hours (2.61 SD 2.46 versus 3.23 SD 2.88; P = 0.351), and 48 hours (2.00 SD 2.19 versus 2.03 SD 2.51; P = 0.745). Pain scores were higher in the treatment arm at 72 hours (1.74 SD 2.09 versus 1.44 SD 1.87; P = 0.574) and 7 days (1.37 SD 1.76 versus 0.61 SD 1.08; P = 0.031). No P values exceed their Hochberg limits for significance. There was no significant difference in the number of acetaminophen pills (2.93 SD 6.93 versus 1.31 SD 2.96; P = 0.837), NSAID pills (3.56 SD 7.24 versus 2.30 SD 6.51; P = 0.678), and narcotic pills (4.17 SD 5.96 versus 4.36 SD 5.10; P = 0.325) between the 2 groups.
CONCLUSION:
Intraoperative dexamethasone administration during CTR did not reduce pain levels or number of narcotic pain pills taken in the first postoperative week. Further research evaluating non-narcotic pain reducing modalities for CTR is warranted.
